ADAndré Gundersen Deslauriers

André Gundersen Deslauriers

*This is an algorithmically generated author record based on publicly available information.

André Gundersen Deslauriers has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms

    by Jonas Thier, Sophia Hofmann, Katharina M. Kirchhof, Gabriele Todisco, Teresa Mortera-Blanco, Ingrid Lilienthal, Dimitris C. Kanellis, Indira Barbosa, Ann-Charlotte Björklund, André G. Deslauriers, et al.

    Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS- SF3B1 ) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia. Precision medicine approaches for MDS- SF3B1 remain challenging due to both the complexity of the mis-splicing landscape and its evaluation in disease-accurate models. To uncover novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells and analyzed via unsupervised splicing event profiling using full-length RNA sequencing. This identified SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ), which encodes a key E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) introduced protein instability and decreased total UBA1 levels, rendering mutated cells susceptible to the small-molecule UBA1 inhibitor TAK-243. Analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, absent in other splicing factor-mutated MDS cases or healthy controls. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell numbers in colony-forming assays. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.


  • Open Access

    SF3B1 -mutant mis-splicing of UBA1 confers a targetable therapeutic vulnerability through UBA1 inhibition

    by Jonas Thier, Sophia Hofmann, Katharina M Kirchhof, Gabriele Todisco, Teresa Mortera-Blanco, Indira Barbosa, Ann-Charlotte Björklund, André G Deslauriers, Elli Papaemmanuil, Eirini P Papapetrou, et al.

    SF3B1 mutation-driven myelodysplastic syndromes (MDS- SF3B1 ) arise due to somatic mutation in the splicing factor SF3B1 gene. SF3B1 mutations induce RNA mis-splicing and loss of expression of critical genes for erythropoiesis, leading to erythroid dysplasia and ultimately refractory anemia. The development of precision medicine approaches for MDS- SF3B1 is hampered by the complexity of the mis-splicing landscape and its evaluation in disease-accurate model systems. To identify novel RNA mis-splicing events, isogenic SF3B1 K700E and SF3B1 WT iPSC lines from an MDS- SF3B1 patient were differentiated into hematopoietic cells in vitro and subjected to unsupervised splicing event analysis using full-length RNA sequencing data. This revealed SF3B1 K700E -specific mis-splicing of ubiquitin-like modifier activating enzyme 1 ( UBA1 ) transcripts, which encode the essential E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing ( UBA1 ms ) preserved UBA1 ms mRNA but not protein expression. Consequently, UBA1 ms diminished the pool of functional UBA1, sensitizing SF3B1 K700E cell lines to the small-molecule UBA1 inhibitor TAK-243. Finally, analysis of CD34 + RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1 ms in MDS- SF3B1 patients, without detection in other splicing factor-mutated MDS patients, or in healthy individuals. TAK-243 selectively targeted MDS- SF3B1 primary CD34 + cells and reduced mutant cell number in colony-forming unit studies. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1 ms as a novel therapeutic vulnerability in SF3B1 -mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS- SF3B1 treatments.

  • Open Access

    Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs

    by Georgios Asimomitis, André G. Deslauriers, Andriana G. Kotini, Elsa Bernard, Davide Esposito, Malgorzata Olszewska, Nikolaos Spyrou, Juan Esteban Arango Ossa, Teresa Mortera-Blanco, Richard Patrick Koche, et al.

    SF3B1K700E is the most frequent mutation in myelodysplastic syndrome (MDS), but the mechanisms by which it drives MDS pathogenesis remain unclear. We derived a panel of 18 genetically matched SF3B1K700E- and SF3B1WT-induced pluripotent stem cell (iPSC) lines from patients with MDS with ring sideroblasts (MDS-RS) harboring isolated SF3B1K700E mutations and performed RNA and ATAC sequencing in purified CD34+/CD45+ hematopoietic stem/progenitor cells (HSPCs) derived from them. We developed a novel computational framework integrating splicing with transcript usage and gene expression analyses and derived a SF3B1K700E splicing signature consisting of 59 splicing events linked to 34 genes, which associates with the SF3B1 mutational status of primary MDS patient cells. The chromatin landscape of SF3B1K700E HSPCs showed increased priming toward the megakaryocyte- erythroid lineage. Transcription factor motifs enriched in chromatin regions more accessible in SF3B1K700E cells included, unexpectedly, motifs of the TEA domain (TEAD) transcription factor family. TEAD expression and transcriptional activity were upregulated in SF3B1-mutant iPSC-HSPCs, in support of a Hippo pathway-independent role of TEAD as a potential novel transcriptional regulator of SF3B1K700E cells. This study provides a comprehensive characterization of the transcriptional and chromatin landscape of SF3B1K700E HSPCs and nominates novel mis-spliced genes and transcriptional programs with putative roles in MDS-RS disease biology.


  • Open Access

    Acute Myeloid Leukemia iPSCs Reveal a Role for RUNX1 in the Maintenance of Human Leukemia Stem Cells

    by Josephine Wesely, Andriana G. Kotini, Franco Izzo, Hanzhi Luo, Han Yuan, Jun Sun, Maria Georgomanoli, Asaf Zviran, André G. Deslauriers, Neville Dusaj, et al.


  • Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin

    by Kristian Reckzeh, Hüsün Kizilkaya, Alexandra Søgaard Helbo, Montserrat Estruch Alrich, André Gundersen Deslauriers, Amit Grover, Nicolas Rapin, Fazila Asmar, Kirsten Grønbæk, Bo Porse, et al.

    Key Points: EMCN is a novel marker of human HSCs. EMCN is a more specific marker of HSCs than CD34 as it can discriminate HSCs from lineage-committed HPCs.